ICBP90, inverted CCAAT box-binding protein of 90 kDa, has been reported as a regulator of topoisomerase IIa expression. We present evidence here that ICBP90 binds to methyl-CpG when at least one symmetrically methylated-CpG dinucleotides is presented as its recognition sequence. A SET and RING finger-associated (SRA) domain accounts for the high binding affinity of ICBP90 for methyl-CpG dinucleotides. This protein constitutes a complex with HDAC1 also via its SRA domain, and bound to methylated promoter regions of various tumor suppressor genes, including p16
Introduction
Methylation of CpG dinucleotides plays an essential role in regulation of gene expression. Five proteins that contain methyl-CpG-binding domains (MBDs), namely MeCP2, MBD1, MBD2, MBD3, and MBD4, are considered to be critical for interpretation of the DNA-methylation signal (Ballestar and Wolffe, 2001) . The MBD domain is essential for these proteins to bind to methylated-DNA with little specificity for flanking nucleotide sequences. In addition, a methyl-CpG-binding protein lacking the MBD domain, Kaiso, was reported (Prokhortchouk et al., 2001; Daniel et al., 2002) . Kaiso was identified as a p120 ctn -interacting protein (Daniel and Reynolds, 1999) , a member of MeCP1 complex (Prokhortchouk et al., 2001) as well as that of the N-CoR complex (Yoon et al., 2003) . Kaiso can bind a specific consensus sequence, but can also bind to methyl-CpG dinucleotides by its zinc-finger (Daniel et al., 2002) .
In earlier studies, we noted an interesting correlation between the methylation pattern of intron 1 of EGR2 and the expression level of the gene (Unoki and Nakamura, 2003a) . Through a line of analyses designed to clarify the transcriptional regulation of EGR2, we identified inverted-CCAAT-box-binding protein of 90 kDa (ICBP90) as a novel methyl-CpG-binding protein and as a candidate of transcriptional regulator of EGR2, but we could not conclude that ICBP90 was a transcriptional regulator of EGR2. However, since the protein seemed to play important roles in transcriptional regulation in general by its unique feature, we decided to further examine its biological functions.
ICBP90 was first isolated as a protein that bound to a CCAAT box in the promoter region of the topoisomerase IIa gene (Hopfner et al., 2000 (Hopfner et al., , 2002 . ICBP90 localizes in nuclei and contains an ubiquitin-like (UbL) domain, a leucine zipper, a zinc-finger of the PHD-finger type, SRA domain, two nuclear localization signals (NLSs), and a zinc-finger of the ring-finger type. Its discoverers found abundant expression of ICBP90 mRNA in actively proliferating tissues; similarly, ICBP90 protein was highly expressed in fibroblasts at the active proliferative stage, but not after the cells reached confluence (Hopfner et al., 2000) . Overexpression of ICBP90 was observed in breast carcinomas, indicating a possible role in human mammary carcinogenesis; those experiments also suggested that E2F-1 was an upstream regulator of ICBP90 (Mousli et al., 2003) . Hopfner et al. (2000) also predicted several putative phosphorylation sites for cAMP/cGMP-dependent kinase in the ICBP90 protein, and recently the protein kinase A was shown to phospholylate one of the predicted phosphorylation sites (Trotzier et al., 2004) . Moreover, expression of ICBP90 decreases after DNA damage involving the p53/p21 WAF1 -dependent pathway, and its downregulation contributes to arrest of the cell cycle at the G1/S transition (Arima et al., 2004) .
Np95, a 95-kDa nuclear protein in the mouse, is considered the murine counterpart of human ICBP90 (Fujimori et al., 1998; Uemura et al., 2000; Miura et al., 2001) . Recently, it was revealed that Np95 and NIRF, another protein in the same family as ICBP90 (Mori et al., 2002) , had ubiquitin ligase activity (Citterio et al., 2004; Mori et al., 2004) . Np95 ubiquitinates histones, especially histone H3, through its RING finger domain (Citterio et al., 2004) . Expression of Np95 is induced by E1A protein and serum, and repression of Np95 expression suppresses cell proliferation (Bonapace et al., 2002) . NIRF ubiquitinates a function-unknown protein, PCNP , and induces G1 arrest through the association with Cdk2 .
In the work reported here we demonstrated that ICBP90 binds with high affinity to methylated CpGs through its SRA domain and recruits HDAC1 through the same domain. ICBP90, whose expression is directly regulated by E2F-1, targets methylated promoter regions of various tumor suppressors. A hypothesis proposed here involves E2F-1, ICBP90, HDAC1, and tumor suppressors in a model pathway that could be important for carcinogenesis.
Results
Purification and identification of a novel property of ICBP90, ability to bind methyl-CpG
We isolated ICBP90 (approved symbol is UHRF1) as a 90-kDa molecule binding to a methylated 1.2-kb DNA fragment corresponding to the CpG islands of intron 1 of the EGR2 gene by DNA-protein pull-down assay (Unoki and Nakamura, 2003a) and subsequent LC/MS-MS analysis. No binding to ICBP90 occurred when those sites were unmethylated (data not shown). We subsequently examined ICBP90 function on EGR2 transcription, but failed to find any specific effects on it. However, since all known methyl-CpG-binding proteins have been shown to have important biological functions (Ballestar and Wolffe, 2001), we decided to investigate the biological effect of ICBP90 as a novel methyl-CpG-binding protein.
To delineate the specific binding target of ICBP90, we prepared three 400-bp portions of the EGR2 fragment (F, M, B), and examined their binding affinities for Figure 1 Target sequence of ICBP90. (a) Schematic representation of CpG sites in EGR2 gene, and sequence of a 1.2-kb portion of intron 1. Proteins binding to each methylated or unmethylated biotin-labeled DNA probe were purified on streptavidin-sepharose, and immunodetected by anti-ICBP90 antibody. UM, unmethylated; M, methylated. (b) EMSA-Western blotting analysis of oligonucleotides containing various numbers of CpGs. Each sequence of the oligonucleotides is described at the bottom. UM, unmethylated; M, methylated. Anti-FLAG antibody was for negative control. We used the nuclear extract prepared from cells transfected with full-length ICBP90-expressing plasmid. The left-end lane does not contain either oligonucleotides or antibodies. (c) Comparison of binding of ICBP90 to various methylated oligonucleotides on a gel. Anti-ICBP90 antibody was used for detection of the oligonucleotide/protein complex ICBP90 binds to methyl-CpG with HDAC1 M Unoki et al ICBP90 ( Figure 1a ). As ICBP90 bound to all three fragments with almost the same affinity, ICBP90 did not appear to have any obvious sequence specificity for other than methyl-CpG dinucleotides. To further determine the binding affinity of ICBP90, we performed EMSA experiments combined with immunodetection, using methylated or unmethylated 25-bp oligonucleotides ( Figure 1b ) and anti-ICBP90 antibody. The band detected in a lane of protein/oligonucleotide mixture is in fact the ICBP90/oligo complex because the shift band was disappeared by addition of the antibody, although the band obtained from the experiment using unmethylated-CpG oligonucleotide and anti-ICBP90 antibody cannot be distinguished from that obtained from the experiment using methylated-CpG oligonucleotide. As the result, we found that ICBP90 required at least one symmetrically methyl-CpG dinucleotides as its recognition sequence, and again showed little specificity for flanking nucleotide sequences (Figure 1b, c) . These experiments revealed, moreover, that this protein has significantly stronger binding affinity for methyl-CpG dinucleotides than it does for its reported target sequence in the topoisomerase IIa promoter ( Figure 1b , c: oligo7, TopoII ICBP2).
Identification of the methyl CpG-binding domain of ICBP90
We constructed various plasmid clones, each of which encoded a part of the ICBP90 protein (Figure 2a ), checked the sizes of the expressed proteins (Figure 2b) , and then examined their binding ability to methyl-CpGs in double-stranded oligonucleotides (oligo-1) by EMSA-Western analysis. As shown in Figure 2c , the SRA domain seemed to be essential for binding; the mutant construct including the SRA domain (ICBP90 SRA-FLAG) could bind to the methylated oligonucleotides ( Figure 2c upper right panel). We examined the binding affinity using another oligonucleotide and found that the ICBP90 SRA-FLAG could bind to the methylated one, but not the unmethylated one. Since EMSA-Western analysis was performed using nondenaturing gels, only proteins with low isoelectric points (PI) could enter the gel and be electrophoresed without binding to DNA (negative charge). Therefore, ICBP90DSRADRING (PI: 5.10) and ICBP90UbL (PI: 5.09) were detected without binding to oligonucleotides (Figure 2c , lower panels, the left lane in each panel). We judged that these proteins did not bind to methylated oligonucleotides, since we observed no bands reflecting different mobilities (Figure 2c , lower panels, the right lane in each panel). NIRF, a protein related to ICBP90, and Np95, the murine homologue of ICBP90, also bound to oligonucleotides containing methylated CpGs through their own SRA domains (Figure 2d ).
Targets of endogenous ICBP90
Since the promoters of various tumor suppressor genes are highly methylated in several cancer-cell lines, we performed chromatin immunoprecipitation (ChIP) analysis to investigate the biological function of ICBP90. After confirming the absence of homozygous deletions, except in the p16 INK4A and p14 ARF genes in A549 cells (Miki et al., 2000) , we determined the methylation status of promoter in six tumor suppressor genes by methylation-specific PCR, using sodium bisulfite-treated genomic DNAs and published primer sets (Supplementary Table S1, Figure 3a ). We found no discrepancies with previously reported results in terms of methylation status, except for the p14 ARF gene in SW480 cells (Burri et al., 2001) . Then, we performed ChIP analysis using anti-ICBP90 antibody. Figure 3b shows that endogenous ICBP90 bound to methylated promoters of all six genes, but not when they were unmethylated with two exceptions; one was the promoter region of RARb gene in HCT116 cells and the other was the promoter region of p14 gene in SW480 cells; these promoters were methylated, but the binding of ICBP90 was not detected. The status of methylation and the results of ChIP assay were highly concordant, indicating that ICBP90 would be likely to bind to the methylated DNAs in vivo. As we had shown earlier, the affinity of ICBP90 to the promoter region of topoisomerase IIa was very low (Figure 1b Figure 4a ). ICBP90 immunocomplexes prepared from lysates of HEK293T cells expressing exogenous ICBP90 revealed higher HDAC activities than the control, a normal mouse IgG complex. Since the substrate for the assay is effectively deacetylated by HDAC1 and HDAC2 (manufacturer's data), we investigated whether ICBP90 could form complexes with either or both of those major histone deacetylases. Immunoprecipitation experiments (Figure 4b ) revealed that endogenous ICBP90 could interact with endogenous HDAC1 but not with HDAC2. We then determined which domain(s) of ICBP90 had bound to HDAC1, using plasmid constructs encoding parts of the ICBP90 protein. Among these constructs, ICBP90DRING and ICBP90 SRA-FLAG could bind to HDAC1 (Figure 4c , upper panels), while neither ICBP90DSRADRING nor ICBP90UbL could bind to HDAC1 (lower panels), indicating that ICBP90 binds to HDAC1 through its SRA domain. The SRA domains of Np95 and NIRF proteins revealed binding ability toward HDAC1 as well (Figure 4d ).
Downregulation of ICBP90
To clarify the role of ICBP90 in cell proliferation, we suppressed expression of ICBP90 by siRNAs. Transfection of three plasmids, each designed to express siRNA against ICBP90, into HEK293 cells suppressed expression of ICBP90 protein (Figure 5a ), and inhibited cell growth compared with cells transfected with siRNA against EGFP (Figure 5b ). The same result was obtained when we used HCT116 cells. Therefore, ICBP90 expression seems to be correlated with cellproliferation status.
Cell-proliferation effect of ICBP90
Since ICBP90 is expressed at a high level in cells during the proliferation phase and is low or absent in cells at confluence (Hopfner et al., 2000) , we checked the expression status of this protein in various cancer cell lines. We chose three lines that revealed contact inhibition (LNCap.FGC, PC3, and DBTRG-05MG) and two (HCT116 and Ishikawa3-H-12) that did not, according to their cellular morphologies in confluent conditions (Figure 6a ). Contact inhibition-positive cells stopped growing but sustained their shape and size, while negative cells kept growing even after contact with neighboring cells, and became smaller. As shown in Figure 6b , expression of ICBP90 protein was decreased in the three contact inhibition-positive lines at the confluent stage compared to the growing phase, but was unchanged in the two negative lines. The suppression of ICBP90 expression was confirmed by RT-PCR (Figure 6c ). Expression levels of two ICBP90-related genes, E2F-1 and topoisomerase IIa, correlated well with that of ICBP90 but expression levels of p16 INK4A and p14 ARF did not. Although downregulation of ICBP90 by p53/p21-dependent DNA-damage checkpoint signals was reported recently (Arima et al., 2004) , expression of p21 WAF1 was not always increased by contact- Supplementary Table S1 . (b) ChIP assay using anti-ICBP90 antibody and the three cancer cell lines. As a negative control, no antibody immunoprecipitation (À) and anti-b-actin immunoprecipitation (ab-actin) were performed. The PCR conditions are also described in Supplementary Table S1 ICBP90 binds to methyl-CpG with HDAC1 M Unoki et al inhibition signals (Figure 6c ), suggesting that different signals might be inducing downregulation of ICBP90 under confluent conditions. A scratching assay using contact inhibition-positive DBTRG-05MG cells ( Figure 6d ) revealed a significant accumulation of endogenous ICBP90 protein during the proliferative phase. This accumulation was confirmed in other contact inhibition-positive cells (data not shown).
Identification of an additional binding partner of ICBP90
Moreover, we identified an approximately 170 kDa novel ICBP90-binding partner designated ICBP90-binding protein 1 (UHRF1BP1) by immunoprecipitation using anti-ICBP90 antibody and subsequent LC/ MS-MS analysis (Accession numbers; NM_017754 and AB126777: Figure 7a ). The gene encoding UHRF1BP1 is located at chromosome 6p21 and spans an 81.3-kb genomic region with 21 exons (gi|27498529); its product has an NLS in the N-terminal region, a leucine-zipper motif, and a coiled-coil domain in its C-terminal region by computer prediction. We confirmed binding between exogenous ICBP90 and FLAG-tagged UHRF1BP1 by immunoprecipitation (Figure 7b, left) . FLAG-tagged UHRF1BP1 also bound to myc-tagged HDAC1 (Figure 7b right) . UHRF1BP1 also formed a complex with itself ( Figure 7c ). Expression levels of UHRF1BP1- 
Increased expression of ICBP90 in primary breast cancers
The data shown above, combined with reports of overexpression of ICBP90 in breast cancer samples (Hopfner et al., 2002; Mousli et al., 2003) , indicate a presumptive importance of ICBP90 in human carcinogenesis. Our own cDNA-microarray data ( Figure 1a) . The result was also confirmed by immunohistochemistry (Supplementary Figure 1b) . Figure 7d illustrates a model for the ICBP90 signaling pathway, from proliferation signals to carcinogenesis, proposed on the basis of previous reports and our observations described here.
Discussion
Methylation of CpG-dinucleotides is receiving increasing attention because of its important role in the regulation of gene expression. Among the five methylCpG-binding proteins that have been reported so far, MBD1, MBD2, MBD4, MeCp2, and Kaiso, the last is the only one that binds to methylated CpGs through its zinc-finger domain; the others bind through 'MBD' domains (Ballestar and Wolffe, 2001, Prokhortchouk et al, 2001) . We have reported here the second example of a methyl-CpG-binding human protein, ICBP90, which has no MBD domain; this molecule binds through an SRA domain (Baumbusch et al., 2001) .
The SRA domain of the murine homologue of ICBP90, Np95, has histone H3-binding activity (Citterio et al., 2004) . Since our experiments revealed that Np95 could also bind methyl-CpGs, we suggest that methylated DNA twisted around histone H3 might be the primary target for Np95 and ICBP90 in vivo. This hypothesis is supported by the results of our ChIP assay, which showed that ICBP90 did not bind to unmethylated tumor suppressor genes in vivo. We demonstrated that the protein could bind to DNA segments containing even a single symmetrically methyl-CpG dinucleotides. Sequences flanking methyl-CpG did not appear to be very important but did affect binding affinity to some extent, as is the case with other methyl-CpG-binding proteins.
ICBP90 was previously reported to be a transcriptional regulator of topoisomerase IIa through interaction with the inverted CCAAT box (ICB2) in the gene's promoter (Hopfner et al., 2000) . However, we found that ICBP90 had greater binding affinity for methylCpG than for the reported sequences, indicating that ICBP90 could play a much wider role in transcriptional regulation, through binding to methylated-DNA. Following up on that idea, we examined binding of ICBP90 to the promoter region of tumor suppressor genes where MBD2 and MeCp2 are known to bind (MagnaghiJaulin et al., 1998; Nguyen et al., 2001) and found that ICBP90 also bound to the methylated promoter in those genes, with two exceptions. These discrepancies were due to the effects of chromatin structures, or the presence of other binding proteins that competitively work to the same region. Since some methyl-CpGbinding proteins are constituents of HDAC complexes (Ballestar and Wolffe, 2001; Prokhortchouk et al., 2001) , we examined the possibility that ICBP90 also could be involved in the complexes. Our experiments revealed that complexes containing ICBP90 did possess HDAC activity, and that ICBP90 was interacting with However, at present, we have no direct evidence that the binding of ICBP90 suppresses the expression of these genes. Methylated promoters of tumor suppressor genes are also targets of other methyl-CpG-binding proteins such as MeCP2 and MBD2. Hence, it makes very difficult to examine the effect of ICBP90 alone in vivo because cells are likely to have several alternative pathways to suppress gene expressions thorough the methylated promoter. Moreover, since expression of p16 INK4A and p14 ARF was not increased under the confluent status at which the expression of ICBP90 was decreased, we need to investigate downstream genes specific to ICBP90 by comprehensive expression analysis combined with methylation status analysis.
We examined ICBP90 expression in cancer cell lines and found significant decreases even in cancer cell lines whose growth was suppressed by contact inhibition. Therefore, ICBP90 seemed to express in proliferative cell phase by some proliferative signals that were conveyed continuously after reaching to the confluence stage in contact-inhibition-negative cells. We successfully demonstrated by scratching assay the expressional differences of the protein in the proliferative cells and the quiescent cells. This result indicates that the expression of ICBP90 may be a useful marker for proliferative stage of cells. On the other hand, ICBP90 expression was significantly downregulated by serum starvation or by DNA damage (Supplementary Figure  2a, 2b) , and downregulation of ICBP90 by siRNAs caused growth suppression. Hence, ICBP90 might be a good target for development of cancer treatment, although it is required to find out the way to avoid the growth suppression of normal proliferative cells such as born marrow where ICBP90 is expressed.
We also isolated an additional protein, UHRF1BP1, that is one of the members to constitute the ICBP90 complex, by immunoprecipitation using anti-ICBP90 antibody. We presented the data indicating that the interaction of ICBP90 with UHRF1BP1 caused relocation of ICBP90 (Supplementary Figure 3a) , and that overexpression of UHRF1BP1 might induce inhibition of cell growth (Supplementary Figure 3b) . Therefore, we considered that UHRF1BP1 might be a negative regulator of cell growth like a tumor suppressor, but further detailed investigation should be required to define the function of this potein. Recently Arima et al. (2004) reported that downregulation of ICBP90 by adriamycin treatment was involved in p53/p21 WAF1 -dependent growth-arrest pathway. As a candidate of transcriptional regulator of ICBP90, E2F-1 has been reported (Mousli et al., 2003) . We found by ChIP analysis that E2F-1 bound to intron 1 of ICBP90, which contains two E2F-1-binding motifs (Supplementary  Figure 4) . Based on our observation and previous reports, we propose a model for the ICBP90 signaling pathway involved in E2F-1 regulation (Figure 7d) .
Overexpression of ICBP90 in breast cancers (Hopfner et al., 2002; Mousli et al., 2003) was also confirmed by 
Materials and methods

Cell lines
Ishikawa3-H-12 was obtained from Dr M Nishida at Tsukuba University (Tsukuba, Japan The microarray experiment using the samples was performed as described previously (Nishidate et al., 2004) .
Purification of methyl-CpG-binding proteins
Proteins binding to methylated CpGs were purified using a methylated-DNA probe derived from intron 1 of EGR2. The protocol was described in our previous report (Unoki and Nakamura, 2003a) . The purified proteins were separated and stained by CBB. Specific bands were cut out and analysed by LC/MS-MS (APRO Life Science Institute, Tokushima, Japan).
Antibodies
Antibodies used here included mouse monoclonal antibody to ICBP90 (612264; BD Transduction Laboratories, San Diego, CA, USA), mouse monoclonal antibody to b-actin (AC-15; SIGMA, St Louis, MO, USA), rabbit polyclonal antibody to HDAC1 (H-51; Santa Cruz), rabbit polyclonal antibody to HDAC2 (H-54; Santa Cruz), FLAG M2 mouse monoclonal antibody (F-3165; SIGMA), FLAG rabbit antibody (F-7425; SIGMA), mouse monoclonal antibody to Myc tag (9E-10; Santa Cruz), rabbit monoclonal antibody to Myc tag (A-14; Santa Cruz), rabbit polyclonal antibody to E2F-1 (C-20, Santa Cruz), and normal mouse IgG (sc-2025).
Construction of expression plasmids
All sequences for cloning were amplified by PCR using KODPlus (TOYOBO, Tokyo, Japan). The entire coding sequence of ICBP90, and of deletion mutants designated ICBP90DRING, ICBP90DRINGDSRA, and ICBP90UbL, were cloned into pcDNA3.1( þ ) (Invitrogen, Carlsbad, CA, USA). The entire coding sequence of UHRF1BP1 and ICBP90 SRA were cloned into pFLAG s -CMV-5a (SIGMA). The entire coding sequence of HDAC1 was cloned into pcDNA3.1/Myc-His & A (Invitrogen). The entire coding sequence of UHRF1BP1 and the SRA domains of NIRF and Np95 were cloned into pCMV-Myc (Clontech, Palo Alto, CA, USA). HDAC1-FLAG expression vector was provided by Dr S Ishii (RIKEN, Tsukuba, Japan).
EMSA combined with Western blotting
HEK293T cells were plated and each culture was transfected by lipofection (FuGENE TM 6 Transfection Regent; Roche) with 8 mg of an indicated plasmid. After 48 h, the cells were harvested and whole-cell proteins were lysed in high salt buffer (20 mM ES at pH 7.6, 20% glycerol, 500 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM DTT, 0.1% NP40). The extracts were incubated for 1 h at room temperature under usual EMSA condition with appropriate nonlabeled, doublestranded oligonucleotides, and indicated antibody. Doublestranded oligonucleotides were methylated by incubation with SssI. Each protein-oligonucleotide complex was separated in native 5% polyacrylamide gel, transferred to a nitrocellulose membrane, and immunoblotted using appropriate antibodies.
Sodium bisulfite modification and methylation analysis
Genomic DNAs were treated with sodium bisulfite according to a method described previously (Unoki and Nakamura, 2003a) . For methylation-specific PCR, the treated DNA fragments were amplified under the conditions described in Supplementary Table S1 .
ChIP analysis
ChIP assays were performed using acetyl-histone H3 ChIP Assay Kits (Upstate Biotechnology, Waltham, MA, USA) as recommended by the manufacturer, except that antibodies against ICBP90, E2F-1, and b-actin were used in this study. PCR primer sets and annealing temperatures for the analysis are described in Supplementary Table S1 .
HDAC colorimetric activity assay
HEK293T cells were transfected with ICBP90 pcDNA3.1( þ ) and harvested after 24-h culture. Cellular proteins were extracted in NP40-based lysis buffer (0.1% NP40, 150 mM NaCl, 50 mM Tris-HCl), and immunoprecipitated by anti-ICBP90 antibody or by normal mouse IgG as a negative control. The immunocomplexes were collected in protein A/G PLUS-Agarose (sc-2003, Santa Cruz), washed, and measured for HDAC activity using HDAC Colorimetric Activity Assay/ Drug Discovery Kits (AK-501, BIOMOL s Research Laboratories, Plymouth Meeting, PA, USA) according to the manufacturer's recommendations. The light emission of deacetylated substrate was quantified at 405 nm.
Immunoprecipitation and immunoblotting
HEK293T cells were seeded 12-24 h before transfection and transfected with 8 mg of plasmid in FuGene 6 regent (Roche). MG132 (10 ug/ml) was added 6 h prior to harvest; 48 h after transfection, the cells were lysed in NP40-based lysis buffer (0.1% NP40, 150 mM NaCl, 50 mM Tris-HCl). Immunoprecipitation experiments were performed using the indicated antibodies with protein A/G PLUS-Agarose (sc-2003, Santa Cruz) . Each precipitate was washed and proteins were eluted with sample buffer. Immunoblotting was performed by standard protocols. The corresponding nucleotides of ICBP90 cloned into an siRNA expression vector, psiU6BX3, constructed previously by us (Shimokawa et al., 2004) were as follows: si-1: 1480-1500 si-2: 857-875, and si-3: 2123-2141. Each plasmid construct was transfected to HEK293 cells, and the cells were selected by G418 (900 ug/ml). At 48 h after transfection, the cells were harvested for Western blotting; after 9 days, and the cell viability was evaluated by MTT assay (Unoki and Nakamura, 2003b) .
Diaminobenzidine tetrahydrochloride (DAB) staining
DBTRG-05MG cells were cultured at confluent status for 3 days and scratched by a disposable plastic PCR tip. At 20 h after scratching, the cells were fixed by 4% paraformaldehyde and treated for 3 min with 0.1% Triton X-100. DAB staining was carried out using DAKO EnVision Systems (K1390, DakoCytomation, Carpinteria, CA, USA) according to the manufacturer's recommended protocol. Anti-ICBP90 antibody was used to detect endogenous ICBP90.
Identification of UHRF1BP1
Endogenous ICBP90 protein in HEK293T cells was immunoprecipitated by anti-ICBP90 antibody; proteins binding to ICBP90 were separated and stained by Silver stain MS kit (Wako Pure Chemical Industries, Japan). Specific bands detected only in lanes containing proteins immunoprecipitated by anti-ICBP90 antibody were cut out and analysed by LC/ MS-MS (APRO Life Science Institute).
